Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study

    Access Status
    Fulltext not available
    Authors
    Ashton, E.
    Windebank, E.
    Skiba, M.
    Reid, Christopher
    Schneider, H.
    Rosenfeldt, F.
    Tonkin, A.
    Krum, H.
    Date
    2011
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Ashton, E. and Windebank, E. and Skiba, M. and Reid, C. and Schneider, H. and Rosenfeldt, F. and Tonkin, A. et al. 2011. Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. International Journal of Cardiology. 146 (3): pp. 404-407.
    Source Title
    International Journal of Cardiology
    DOI
    10.1016/j.ijcard.2009.12.028
    ISSN
    0167-5273
    School
    Department of Health Policy and Management
    URI
    http://hdl.handle.net/20.500.11937/33130
    Collection
    • Curtin Research Publications
    Abstract

    Background: Statins are often prescribed for prevention of atherosclerotic outcomes in patients who have chronic heart failure (CHF), if this has an ischaemic etiology. These agents may also possess additional properties, independent of effects on blood lipid levels, which may have an effect on cardiac remodeling. However, beneficial effects were not observed in the recent UNIVERSE trial. Methods: We prospectively planned a sub-study of UNIVERSE to explore relevant mechanistic effects of rosuvastatin, including effects on collagen turnover and plasma coenzyme Q10 (CoQ) levels. Additionally, CoQ levels in CHF patients receiving chronic statin therapy were measured. Results: CoQ levels were significantly reduced after 26 weeks of rosuvastatin statin therapy (n = 32), compared to placebo (n = 37) in CHF patients in UNIVERSE trial. Patients with CHF (n = 56) matched for age, gender and severity of disease who had been taking statins for 12 months or longer had CoQ levels of 847 ± 344 nmol/L, significantly lower than 1065.4 ± 394 nmol/L in UNIVERSE patients at baseline (p = 0.0001). Serum types I and III N-terminal procollagen peptide (PINP and PIIINP), measures of collagen turnover which can contribute to cardiac fibrosis were significantly increased in the rosuvastatin group compared to baseline in UNIVERSE patients (PINP: p = 0.03, PIIINP: p = 0.001). Conclusion: In conclusion putative beneficial effects of statin therapy on cardiac remodeling in UNIVERSE may have been negated by increases in collagen turnover markers as well as a reduction in plasma CoQ levels in these patients with CHF. © 2010 Elsevier Ireland Ltd. All rights reserved.

    Related items

    Showing items related by title, author, creator and subject.

    • Statin-induced myopathy and the benefit of oral administration of coenzyme Q10
      Kurniawan, Dede Indra (2007)
      Background. Muscle cramps are one of the adverse affects suffered by hypercholesterolemia patients who are treated with statins. Besides reducing cholesterol levels, statins also reduce coenzyme Q10 (CoQ10) blood levels. ...
    • Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
      Yusuf, S.; Bosch, J.; Dagenais, G.; Zhu, J.; Xavier, D.; Liu, L.; Pais, P.; López-Jaramillo, P.; Leiter, L.; Dans, A.; Avezum, A.; Piegas, L.; Parkhomenko, A.; Keltai, K.; Keltai, M.; Sliwa, K.; Peters, R.; Held, C.; Chazova, I.; Yusoff, K.; Lewis, B.; Jansky, P.; Khunti, K.; Toff, W.; Reid, Christopher; Varigos, J.; Sanchez-Vallejo, G.; McKelvie, R.; Pogue, J.; Jung, H.; Gao, P.; Diaz, R.; Lonn, E.; HOPE-3 Investigators (2016)
      BACKGROUND: Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated ...
    • Statins: Antimicrobial resistance breakers or makers?
      Ko, H.; Lareu, Ricky R.; Dix, B.; Hughes, J. (2017)
      © 2017 Ko et al. Introduction. The repurposing of non-antibiotic drugs as adjuvant antibiotics may help break antimicrobial resistance (AMR). Statins are commonly prescribed worldwide to lower cholesterol. They also possess ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.